Medexus Pharmaceuticals

MDP.TO

Medical - Pharmaceuticals · Healthcare

Exchange

Toronto Stock Exchange

Winston Score

Winston is worried

Below-average fundamentals — multiple weak pillars.

Data as of Aug 23, 2026 · filings through Mar 31, 2026

How the score breaks down

Quality

Mixed

Growth

Weak

Cash Flow

Weak

Stability

Good

Valuation

Data not available

Track this stock — start free trial

Winston Score History

The full picture

Medexus Pharmaceuticals is a specialty pharmaceutical company that sells prescription drugs in Canada and the United States. Its key products include Rasuvo and Metoject, which are forms of methotrexate used to treat rheumatoid arthritis and certain cancers, as well as Gleolan, a drug used during brain tumor surgery to help surgeons see cancer cells more clearly. Its main customers are hospitals, clinics, and specialist doctors who treat patients with serious conditions.

Medexus makes money by selling these branded specialty drugs directly to healthcare providers and through distribution partners. The company operates primarily in North America and is relatively small, with a market cap around $100 million. Its competitive position relies on holding rights to niche branded drugs that face limited direct competition in their specific forms or indications. The main risk is that the company carries debt from past acquisitions and operates on thin margins, meaning any disruption to its key products — through competition, pricing pressure, or regulatory issues — could significantly hurt its financial results.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-0.4% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-301.9% YoY

YoY Growth Rate

Earnings declining

Insider Activity

8.2%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~2 months

C$7M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Cash watch

Medexus Pharmaceuticals has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

53.8%

Healthy — 53.8% gross margin

Profit after running costs

Operating Margin

6.7%

Modest — 6.7% operating margin

Return on the money invested

ROCE

7.8%

Weak — 7.8% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-8.3%

Shrinking sales (-8.3% YoY)

Profit growth

EPS YoY

-183.5%

Earnings shrinking (-183.5% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

How steady the profit is

EPS Consistency

2/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

3.7%

Thin free cash flow (3.7%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.45

Conservative — low debt load (0.45)

Covers its interest

Interest Cover

1.30x

Dangerous — barely covers interest (1.3x)

Interest coverage between 1 and 3. Profits cover interest, but with little room to spare.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial